Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 37.84 1.83% 0.68
SUPN closed down 0.69 percent on Thursday, January 17, 2019, on 78 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical SUPN trend table...

Date Alert Name Type % Chg
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.83%
Jan 17 Weak + Overbought Other 1.83%
Jan 17 Inside Day Range Contraction 1.83%
Jan 17 Overbought Stochastic Strength 1.83%
Jan 16 Stochastic Sell Signal Bearish 1.12%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.12%
Jan 16 Weak + Overbought Other 1.12%
Jan 16 Outside Day Range Expansion 1.12%
Jan 16 Overbought Stochastic Strength 1.12%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.03%

Older signals for SUPN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Is SUPN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 10 Supernus Pharmaceuticals (SUPN) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
Jan 10 MYL vs. SUPN: Which Stock Is the Better Value Option?
Jan 10 Does Market Volatility Impact Supernus Pharmaceuticals, Inc.’s (NASDAQ:SUPN) Share Price?
Dec 28 Keeping Focused Amidst The Biotech Bear
Dec 21 Supernus to Present at the 2019 J.P. Morgan Healthcare Conference
Dec 21 The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
Dec 20 Supernus Pharma's SPN-812 successful in another late-stage ADHD study
Dec 20 Hedge Funds Aren’t Crazy About Supernus Pharmaceuticals Inc (SUPN) Anymore
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
Dec 20 Supernus Pharma's ADHD drug meets main goal in study on adolescents
See more SUPN news...
Indicators
Indicator Value
52 Week High 61.25
52 Week Low 30.05
Average Volume 650,798
200-Day Moving Average 47.3771
50-Day Moving Average 38.9538
20-Day Moving Average 34.3855
10-Day Moving Average 36.358
Average True Range 1.8282
ADX 23.08
+DI 19.6397
-DI 14.6364
Chandelier Exit (Long, 3 ATRs ) 32.8354
Chandelier Exit (Short, 3 ATRs ) 35.5346
Upper Bollinger Band 38.8098
Lower Bollinger Band 29.9612
Percent B (%b) 0.81
BandWidth 25.733521
MACD Line -0.2816
MACD Signal Line -1.0779
MACD Histogram 0.7963
Fundamentals Value
Market Cap 1.88 Billion
Num Shares 50.7 Million
EPS 1.98
Price-to-Earnings (P/E) Ratio 18.77
Price-to-Sales 8.00
Price-to-Book 8.81
PEG Ratio 1.42
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.14
Resistance 3 (R3) 39.23 38.66 38.81
Resistance 2 (R2) 38.66 38.16 38.62 38.70
Resistance 1 (R1) 37.91 37.84 37.63 37.82 38.59
Pivot Point 37.34 37.34 37.20 37.30 37.34
Support 1 (S1) 36.59 36.84 36.31 36.50 35.73
Support 2 (S2) 36.02 36.52 35.98 35.62
Support 3 (S3) 35.27 36.02 35.51
Support 4 (S4) 35.18